Results 111 to 120 of about 6,429 (163)

Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells. [PDF]

Hum Gene Ther, 2022
Jin J, Wang R, Yang J, Hu H, Wang D, Cai L, Fang Z, Dong S, Hu S, Wang Y, Liu B.   +10 more
europepmc   +1 more source

Arming oncolytic herpes simplex virus with CXCL-11, IL-12 and a single-chain antibody against PD-1 to enhance CAR-T cell therapy in pancreatic ductal adenocarcinoma. [PDF]

Cell Death Dis
Chen X, Ma W, Guan Y, Jin X, Yu J, Zhang S, Zhang N.   +6 more
europepmc   +1 more source

Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1⁺ Myeloid Dendritic Cells. [PDF]

Int J Mol Sci, 2022
Kalus P, De Munck J, Vanbellingen S, Carreer L, Laeremans T, Broos K, Dufait I, Schwarze JK, Van Riet I, Neyns B, Breckpot K, Aerts JL.   +11 more
europepmc   +1 more source

An oncolytic herpes simplex virus armed with IL-12 for treatment of preclinical glioblastoma. [PDF]

Mol Ther Oncol
Jackson JW, Hall BL, Sneiderman C, Webb A, Hancock TJ, Vlasyuk M, Bailey L, Xiaokui M, Solomon IH, Ligon K, Goins WF, Kohanbash G, Chiocca EA, Glorioso JC.   +13 more
europepmc   +1 more source

Multiple strategies to improve the therapeutic efficacy of oncolytic herpes simplex virus in the treatment of glioblastoma. [PDF]

Oncol Lett, 2021
Zhou Z, Tian J, Zhang W, Xiang W, Ming Y, Chen L, Zhou J.   +6 more
europepmc   +1 more source

Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models. [PDF]

Viruses, 2022
Wu Y, Chen X, Wang L, Zhou X, Liu Y, Ji D, Ren P, Zhou GG, Zhao J.   +8 more
europepmc   +1 more source

Oncolytic herpes simplex virus reprograms cancer-associated fibroblasts to enhance antitumor immunity in pancreatic cancer. [PDF]

Mol Ther Oncol
Zhou F, Yang K, Wang H, Han M, Zhang D, Wang J, Wang H, Wang Y, Gong F, Zheng H, Liu Y, Zhao J, Xu M, Cao Y, Zhang C.   +14 more
europepmc   +1 more source

High accumulation of Mx2 renders limited multiplication of oncolytic herpes simplex virus-1 in human tumor cells. [PDF]

Sci Rep, 2021
Ren Y, Chen M, Wu G, Ji D, Zhou GG, Ren PG, Fu W.   +6 more
europepmc   +1 more source

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy. [PDF]

Front Oncol, 2022
Liu Y, Zheng Y, Deng T, Huang Y, Liu Z, Zhan B, Zhou X, Yan R, Ren J, Xing Y, Wu G, Zheng B, Hu G, Wang W, Liu Y, Zhao J, Chen X, Zhou GG.   +17 more
europepmc   +1 more source

4-1BBL-Armed Oncolytic Herpes Simplex Virus Exerts Antitumor Effects in Pancreatic Ductal Adenocarcinoma. [PDF]

Vaccines (Basel)
Gao W, Zhao Z, Bi Y, Li J, Tian N, Zhang C, Pan S, Deng L, Zhang Y.   +8 more
europepmc   +1 more source